Amicus Therapeutics (FOLD) Soars to 52-Week High on ‘Strong Buy’ Reco

Company Performance - Amicus Therapeutics, Inc. (NASDAQ:FOLD) reached a new 52-week high of $10.85 during intra-day trading, closing at $10.55, reflecting a 6.57% increase [1] - The company reported a net income of $17.3 million in Q3, a turnaround from a net loss of $6.7 million in the same period last year [4] - Net product sales increased by 20% year-on-year, reaching $169 million, driven by strong sales from Galafold and Pombiliti + Opfolda [4] Sales Breakdown - Galafold sales amounted to $138 million, a 15% increase from $120.38 million in the same quarter last year [5] - Sales for Pombiliti + Opfolda surged by 45%, totaling $30.7 million compared to $21 million in the previous year [5] Analyst Ratings - Zacks Research issued a "strong buy" recommendation for Amicus Therapeutics, with a consensus price target of $15.90, indicating a potential upside of 50.7% from the latest closing price [2] - Analysts have raised EPS targets for the stock, reflecting optimism about the company's ability to report better-than-expected earnings [3]